Coronary Artery Disease Treatment in India & UAE

Coronary artery disease treatment in India from $1,500. Medical, stenting, and bypass for CAD at Apollo, Medanta, Fortis. 93% success. Expert interventional cardiologists and cardiac surgeons.

Estimated cost: $1,500 – $9,000 · Average stay: 2–10 days

Coronary artery disease (CAD) — also known as coronary heart disease (CHD) or ischaemic heart disease — is the most common cause of death worldwide, responsible for approximately 9 million deaths annually. In India, CAD is responsible for an estimated 25–30% of all deaths, with Indian patients developing CAD at a younger age, with more aggressive disease, and often with a genetic lipid profile (elevated Lp(a), low protective HDL) that places them at substantially higher risk than Western populations. In the UAE and Gulf region, the combination of rapidly rising obesity rates, diabetes prevalence (over 25% in UAE adults), sedentary lifestyles, and high saturated fat diets creates an enormous CAD burden.

CAD occurs when atherosclerotic plaques (deposits of cholesterol, calcium, fibrous tissue, and inflammatory cells) progressively narrow the coronary arteries — the three main blood vessels (left anterior descending, left circumflex, and right coronary artery) that supply oxygen and nutrients to the heart muscle. As the narrowing progresses, the heart muscle receives inadequate blood supply during exertion (causing angina — chest pain); when a plaque ruptures suddenly and a blood clot blocks the artery completely, a heart attack (myocardial infarction) occurs.

The range of CAD is vast: from mild, single-vessel disease fully manageable with medications alone, through moderate coronary disease requiring angioplasty and stenting, to severe triple-vessel or left main disease requiring bypass surgery. The treatment strategy for each patient is determined by the Heart Team — a collaborative assessment by an interventional cardiologist and cardiac surgeon, reviewing the coronary angiogram, SYNTAX score, patient comorbidities, and patient preferences — to individualize the most effective and durable treatment plan.

India's cardiac centers offer the complete CAD treatment spectrum — from comprehensive cardiovascular risk modification programs through to complex bifurcation stenting, left main PCI, and total arterial revascularization bypass surgery — at costs that are 70–90% below Western equivalents. Gaf Healthcare navigates this full spectrum for international patients with CAD, from initial coronary angiography through to definitive revascularization and long-term secondary prevention management.

What is Coronary Artery Disease and How Does it Progress?

Coronary artery disease develops silently over decades. The atherosclerotic process begins in the teenage years with early fatty streaks — cholesterol deposits in the arterial wall — that gradually grow into fibrous plaques containing a lipid core, foam cells, smooth muscle cells, and a fibrous cap separating the plaque from the blood. The plaque progressively enlarges, narrowing the artery. By the time a coronary artery is 50% narrowed, it is typically detectable by coronary angiography or CT angiography; above 70%, blood flow during exercise is impaired.

Stable CAD: Gradual plaque growth causing predictable, exertional angina. The heart muscle receives adequate blood at rest but is ischaemic (starved of oxygen) during exercise or stress. Managed by risk factor modification, anti-anginal medications (beta-blockers, nitrates, CCBs), antiplatelet therapy, and revascularization when symptoms are inadequately controlled or when high-risk anatomical features (left main disease, proximal LAD disease with large territory at risk) favor intervention.

Acute Coronary Syndrome (ACS): Plaque rupture or erosion triggers sudden clot formation on the plaque surface, causing acute reduction or complete cessation of coronary blood flow. NSTEMI (partial blockage — elevated troponin, no ST elevation) and STEMI (complete blockage — ST elevation, myocardial infarction) represent the acute, life-threatening end of the CAD spectrum requiring urgent intervention.

The fundamental goals of CAD treatment: prevent acute coronary events (plaque stabilization through lipid-lowering, anti-inflammatory, and antiplatelet therapy); relieve angina symptoms (revascularization — angioplasty or bypass — when medical therapy is inadequate); preserve heart function (protect remaining myocardium); and extend survival (particularly important in high-risk anatomical subsets — left main and three-vessel disease — where CABG is superior to medical therapy alone).

Who Needs Treatment for Coronary Artery Disease?

All patients with confirmed CAD require optimal medical therapy indefinitely. Revascularization (PCI or CABG) is indicated when: symptoms are inadequately controlled by medical therapy; a large area of heart muscle is ischaemic (even in the absence of symptoms — particularly for proximal LAD disease, left main disease, or three-vessel disease with large ischaemic burden); acute coronary syndrome occurs; or when high-risk anatomical features confer a survival benefit with revascularization over medical therapy alone.

The ISCHEMIA trial confirmed that in stable CAD with moderate-to-severe ischaemia but no high-risk anatomy and adequately controlled symptoms, OMT provides equivalent event-free survival to immediate revascularization — challenging the assumption that all ischaemia must be revascularized. The Heart Team role is to identify which patients gain a survival benefit from revascularization (left main, proximal LAD, three-vessel disease with reduced EF) versus those in whom OMT provides equivalent survival with lower risk.

CAD Treatment Approaches

CAD treatment is individually tailored to the patient's symptom burden, anatomical complexity, cardiac function, comorbidities, and preferences.

Optimal Medical Therapy (OMT): The foundation of all CAD management. Aspirin 75–100 mg daily (antiplatelet); high-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg — target LDL below 1.4 mmol/L for established CAD); beta-blocker (for heart rate control, anti-anginal effect, and post-MI mortality benefit); ACE inhibitor or ARB (for hypertension, heart failure, or diabetes with CAD); nitrates (sublingual glyceryl trinitrate for acute angina; long-acting nitrates for prophylaxis); ranolazine (late sodium channel blocker — additional anti-anginal when beta-blockers and nitrates insufficient); PCSK9 inhibitors for LDL above target on maximal statin + ezetimibe.

Percutaneous Coronary Intervention (PCI — Angioplasty and Stenting): Balloon dilation and drug-eluting stent (DES) placement in obstructive coronary lesions causing symptoms or large area of ischaemia. Performed through a catheter in the wrist or groin. Drug-eluting stents (Resolute Onyx, XIENCE Sierra, Ultimaster, Synergy) release medication to prevent scar tissue formation (restenosis). PCI is preferred for: one- or two-vessel disease without high complexity; STEMI (primary PCI as emergency treatment); and NSTEMI with high-risk features. PCI of left main disease (in selected anatomically suitable cases) and complex multi-vessel disease is performed at expert centers with IVUS or OCT guidance and FFR-guided stenting.

Coronary Artery Bypass Grafting (CABG): As discussed in the dedicated heart bypass surgery section — definitive treatment for complex multi-vessel or left main CAD, particularly with diabetes or reduced heart function.

Procedure Steps

1. Risk stratification: symptom assessment (Canadian Cardiovascular Society angina class); exercise testing (treadmill, nuclear perfusion, stress echo); coronary CT angiography (non-invasive); invasive coronary angiography with SYNTAX score.
2. Heart Team assessment: interventional cardiologist + cardiac surgeon review angiogram and patient data; recommendation for OMT alone, PCI, or CABG.
3. Medical optimization: achieve LDL target; BP control; HbA1c optimization in diabetics; smoking cessation; structured exercise program.
4. PCI procedure: coronary angiography; FFR of borderline lesions; angioplasty and DES placement; IVUS/OCT confirmation of optimal stent deployment.
5. CABG (when indicated): as described in bypass surgery section.
6. Post-revascularization: dual antiplatelet therapy × 6–12 months (aspirin + ticagrelor/clopidogrel after PCI); aspirin alone after CABG; statin; ACE inhibitor; beta-blocker.
7. Cardiac rehabilitation: 8–12 weeks structured program; supervised aerobic exercise; dietary education; smoking cessation; stress management.
8. Surveillance: annual cardiovascular risk review; repeat imaging if symptoms recur.

Cost Comparison Worldwide

Country — Range — Savings

--- — --- — ---

United States — $10,000 – $80,000 (medical to CABG) — Baseline

United Kingdom — $5,000 – $40,000 — ~48% savings vs. USA

India — $1,500 – $9,000 (medical or PCI to CABG) — Up to 88% savings vs. USA

UAE — $4,000 – $25,000 — ~70% savings vs. USA

CAD treatment costs in India vary enormously by treatment type. Medical management and risk factor assessment: $500–$1,500. Coronary angiography: $500–$1,000. Single-vessel PCI with DES: $1,500–$3,000. Multi-vessel PCI: $3,000–$6,000. CABG: $4,500–$8,500. Gaf Healthcare provides individualized cost estimates after reviewing your angiogram and Heart Team recommendation.

Recovery & Follow-up

Recovery depends entirely on treatment modality: medical management has no recovery; PCI recovery is 24–48 hours hospital and return to work in 3–5 days; CABG recovery is 7–10 days hospital and 6–8 weeks sternal healing.

All CAD patients need a lifelong approach to secondary prevention: maintaining LDL below 1.4 mmol/L, blood pressure below 130/80 mmHg, HbA1c below 53 mmol/mol in diabetics, smoking cessation, healthy weight, and regular aerobic exercise. Cardiac rehabilitation — starting at 6 weeks after CABG or 2 weeks after PCI — reduces reinfarction by 20–25% and mortality by 25–35%.

Recovery Tips

• Never stop aspirin and clopidogrel/ticagrelor after a drug-eluting stent without cardiology advice — stent thrombosis is life-threatening.
• Target LDL below 1.4 mmol/L — ask your doctor for a PCSK9 inhibitor if statins + ezetimibe are insufficient.
• Exercise 150 minutes of moderate aerobic activity weekly — demonstrated to reduce CAD event rate.
• Annual cardiovascular risk factor review — adjust medications as risk factors change.
• Know your emergency action plan for new chest pain — aspirin and emergency services immediately.
• Cardiac rehabilitation is not optional — attend every session.

Risks & Complications

Untreated or undertreated CAD carries very high mortality and morbidity. Treatment risks are procedure-specific (see angioplasty, bypass surgery, and other specific procedure entries). Long-term risks of CAD despite treatment include: reinfarction (5–15% over 5 years without optimal secondary prevention); heart failure (from accumulated myocardial damage); arrhythmia (requiring ICD); and stroke (from atherosclerosis or AF associated with CAD). Optimal secondary prevention dramatically reduces all these risks.

Why GAF Healthcare

Gaf Healthcare provides comprehensive CAD management coordination — from coronary angiography and Heart Team assessment through to revascularization and cardiac rehabilitation enrollment. Our cardiac coordinators work with both interventional cardiologists and cardiac surgeons to ensure you receive the right treatment for your coronary anatomy, not just the most convenient one. We provide translated angiographic reports and facilitate second-opinion consultations when needed.

Frequently Asked Questions

What is the difference between coronary artery disease and a heart attack?

CAD is the chronic underlying disease — atherosclerotic narrowing of the coronary arteries that develops over decades. A heart attack (myocardial infarction) is an acute event where a plaque ruptures and a blood clot suddenly blocks a coronary artery, cutting off blood supply to heart muscle. CAD causes heart attacks, but CAD can be managed for many years without a heart attack through medical therapy, lifestyle change, and revascularization.

Is coronary artery disease reversible?

CAD cannot be fully reversed, but intensive medical therapy (high-intensity statins, PCSK9 inhibitors, lifestyle changes) can stabilize plaques, prevent rupture, and induce modest plaque regression on imaging. The event rate is dramatically reduced even when plaque burden decreases only modestly, because the remaining plaques are stabilized and less prone to rupture.

When should I choose stenting over bypass surgery?

For single or two-vessel disease with technically suitable anatomy, PCI with drug-eluting stents provides excellent symptom relief and equivalent event rates to CABG. For three-vessel disease, left main disease, or complex multi-vessel disease (particularly with diabetes or reduced heart function), CABG provides superior long-term survival and freedom from repeat revascularization. The Heart Team reviews your angiogram and SYNTAX score to individualize this decision.